Akademik Veri Yönetim Sistemi
J Lit Pharm Sci, cilt.3, sa.45, ss.231-240, 2021 (Hakemli Dergi)
ABS TRACT Obesity is the condition of excessive fatness of the body
beyond acceptable limits. Child obesity rates are on the rise and have
become one of the most serious global health problems of the 21st century. According to the data of the World Health Organization, 6% of
girls and 8% of boys are obese in 2016. Studies conducted in Turkey,
especially in recent years, shows that children and adolescents, the
prevalence of obesity exceeds 10%. There are many factors that cause
obesity in children and adolescents. Factors such as genetic features,
cultural, environmental and behavioral differences cause obesity by disrupting the balance between energy intake and energy expenditure. The
drug called orlistat, a pancreatic lipase inhibitor, was approved by the
United States Food and Drug Administration for long-term obesity
management in adolescents aged 12 years and older. Obesity is associated with various pathophysiological changes that can affect the pharmacokinetics of drugs. Most drugs prescribed for obesity cause
treatment failure with sub-therapeutic or supra-therapeutic concentrations and the risk of drug toxicity. In the presented review, current obesity-specific pharmacokinetics and dosage information for the drugs
most frequently prescribed to hospitalized obese children and adolescents are presented and discussed. It is important to raise the awareness
of clinicians about potential drug therapy failures related to low
organ/tissue drug concentration or drug toxicity in obese children and
adolescents. It is important to closely monitor drug response and side
effects in obese children and adolescents.